Decoy Therapeutics Inc. (DCOY) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, DCOY scores 31 out of 100 for a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars: Fundamental Cash Engine scores 4/20 (ROIC -35%; FCF yield 0%), Whale/13F Flow scores 3/20 (institutional accumulation and options positioning), Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 9/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet scores 10/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). For a prospective investor, the upside case rests almost entirely on the balance sheet and macro pillars, which are the only ones above the lower range. The weakest pillars—cash generation and ownership/insider conviction—are the ones that typically underpin a durable equity thesis, so their low scores weigh heavily against the stock. The shares' recent price move and the RQD verdict point in different directions, and the rating's framing is that short-term price action should not be read as a substitute for the underlying fundamentals. This is an educational breakdown, not personalized advice.

Operating losses appear in every reported period, and FCF is negative in each. Reported net income figures are positive despite operating losses, a divergence the source data does not explain. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. The balance sheet is the strongest pillar in the RQD rating, though the reported debt line is N/A in all periods.

Per the recent news feed, all six items relate to DCOY and carry YELLOW or RED flags. The items are a Moomoo analyst-forecast page, a Yahoo! Finance Canada seasonal returns chart, a Stock Titan SEC filing item dated Oct 19, 2026, a report on the share price holding near $1.17 between $1.11 and $1.23 tagged as merger arbitrage, a Yahoo Finance UK seasonal chart for an unrelated ticker (MTNB), and a RED-flagged "Risk Watch" item referencing a Q3 2024 earnings narrower-than-expected loss with the stock slipping. The feed's summaries are generic, and the source data does not provide the underlying filing contents or verify the merger-arbitrage characterization. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

• What drives the positive reported net income in FY 2025 and FY 2024 when operating income and FCF are both negative?
• What is the company's debt position, given the reported debt line is N/A and Debt/Equity is cited at 0.5?
• What is the nature of the referenced merger-arbitrage activity, and how does it relate to the stock's trading range?
• Who holds the shares, and what are the 13F and insider transaction details behind the whale and insider pillar scores?
• Which products or clinical programs underpin any path to revenue, given reported revenue of $0.0M?